AstraZeneca trial pause is a sign the regulatory process is working: Former FDA chief

AstraZeneca shares were lower in premarket trading after the company on Tuesday said its late-stage trial for a potential coronavirus vaccine had been put on hold due to safety concerns. Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, joins "Squawk Box" to discuss.